Source: Water Ways Technologies.
  • Water Ways (WWT) has received three orders for its medical cannabis IoT smart irrigation and fertilization system
  • The first two orders concern the validation of cannabis genetics and the research and development of cannabis hybrids
  • The third will be implemented in a large Israeli cultivation facility
  • The company expects to deliver and install the systems by the end of Q1 2022
  • Water Ways Technologies is a global provider of water irrigation solutions for agricultural producers
  • Water Ways (WWT) is unchanged trading at $0.285 per share

Water Ways (WWT) has received three orders for its medical cannabis IoT smart irrigation and fertilization system.

The first order is for a system to validate the importation of new cannabis genetics. The structure is designed to achieve optimal growing conditions to meet laboratory test thresholds and establish a new genetic bank for a medical cannabis cultivation facility.

The second order is for a system for the cultivation facility’s research and development room, which will focus on hybrids of new cannabis varieties.

The third order, from a new client, is for a system destined for a 65,000 sq. foot cultivation facility operated by a licensed producer of medical cannabis in Israel.

The company expects to deliver and install the systems by the end of Q1 2022.

Ohad Haber, Water Ways’ Chairman and CEO, stated,

“The orders for our know-how are on the rise. The Israeli market for medical cannabis cultivation is strong to adopt our solution as an industry standard.”

Water Ways Technologies is a global provider of water irrigation solutions for agricultural producers.

Water Ways (WWT) is unchanged trading at $0.285 per share as of 9:30 am ET.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.